Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1243

Shown on this page

Current sort

Live official records

Conditions: Solid Tumor
Interventions: Setidegrasib, Cetuximab, Leucovorin, Oxaliplatin, Fluorouracil, Irinotecan, Nanoparticle albumin-bound-paclitaxel, Gemcitabine, Docetaxel, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Liposomal Irinotecan; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 26
States / cities: Duarte, California • Santa Monica, California • Denver, Colorado + 20 more

Conditions: Endometriosis, Endometrial Diseases
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 135 participants
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: New Haven, Connecticut • Baltimore, Maryland • Nashville, Tennessee

Conditions: Episodic Migraine
Interventions: Xeomin, Placebo; Drug
Lead sponsor: Merz Therapeutics GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 47
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 43 more

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: JSB462, Abiraterone, Enzalutamide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 21
States / cities: La Jolla, California • Santa Monica, California • Denver, Colorado + 18 more

Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 165
States / cities: Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more

Conditions: Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Interventions: Nerandomilast, Placebo matching nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 31
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 25 more

Conditions: Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
Interventions: Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography; Drug · Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 42
States / cities: Buena Park, California • Los Angeles, California • Newport Beach, California + 28 more

Conditions: Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal Cancer
Interventions: Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine, Trastuzumab, Capecitabine, mFOLFOX6, zanidatamab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 26
States / cities: Cerritos, California • Los Angeles, California • Orange, California + 18 more

Conditions: Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions: BNT113, Pembrolizumab; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 15
States / cities: Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 11 more

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Disitamab vedotin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 128
States / cities: Daphne, Alabama • Foley, Alabama • Mobile, Alabama + 103 more

Conditions: Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
Interventions: PF-08046033; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 2 more

Conditions: Solid Tumor
Interventions: AT03-65; Drug
Lead sponsor: Axcynsis Therapeutics Pte Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Denver, Colorado • New Haven, Connecticut • Portland, Oregon + 1 more

About this Yale institution page

What this page lists: ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Yale

Filter and sort this campus

Live official records

A Study of ASP3082 in Adults With Advanced Solid Tumors

Cancer Driving Mutations in Endometriosis Lesions and Development of Progesterone Resistance

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

About this Yale institution page